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ABSTRACT 
Objectives: To investigate whether epigenetic changes can modulate monocytes to produce tissue-
inhibitor of metalloproteinase-1 (TIMP-1) via Fra2 (AP-1 family member), a novel downstream 
mediator promoting fibrogenesis. 
Methods: AP-1 transcription factors and TIMP-1 expression was measured in monocytes from 
systemic sclerosis (SSc) patients and healthy controls (HC). Involvement of Fra2 in the regulation of 
TIMP-1 following TLR8 agonist treatment was investigated using luciferase activity assay and ChIP 
analysis. Expression of TIMP-1 and Fra2 was determined in response to TLR8 treatment and different 
histone modifications including 3’deazaneplanocin (DZNep) and apicidin. HC fibroblasts were co-
cultured with DZNep plus TLR8-treated HC monocytes. 
Results: Upregulation of Fra2 was detected in bleomycin-challenged mice and SSc skin biopsies. 
Enhanced expression of Fra2 and TIMP-1 was correlated in SSc monocytes (p=0.021). The 
expression of Fra1 was significantly (p=0.037) reduced in SSc monocytes. Inhibiting AP-1 activity 
reduced TIMP-1 production in TLR8 stimulated HC and SSc monocytes. ChIP experiments revealed 
binding of Fra-2 to the TIMP-1 promoter. Combination of DZNep plus TLR8 enhanced Fra2 and 
TIMP-1 expression in HC monocytes, whereas TLR8 plus apicidin repressed Fra2 and TIMP-1 
expression. Finally, DZNep plus TLR8-treated HC monocytes induced strong production of α-SMA 
in dermal fibroblasts, which was inhibited by TIMP-1 blocking antibody.  
Conclusions: These data demonstrate a novel role of histone demethylation induced by DZNep on 
Fra2-mediated TIMP-1 production by monocytes in the presence of TLR8 agonist. This consequently 
orchestrates fibroblasts’ trans-differentiation, a key event in the pathogenesis of SSc.  
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Introduction 
Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterised by accumulation of 
extra cellular matrix (ECM) proteins in skin and visceral organs, resulting in organ dysfunction and 
premature death (1). This ECM deposition, predominantly composed of collagen, is observed when 
the homeostasis between matrix metalloproteinases (MMPs) and their natural inhibitors is lost. Tissue 
inhibitor of metalloproteinases-1 (TIMP-1) is a specific inhibitor of MMPs regulating the balance of 
ECM turnover, which is mostly produced by fibroblasts, hepatic stellate cells (HSC) and monocytes. 
Serum concentrations of TIMP-1 are increased in SSc patients, thereby contributing to fibrosis 
development (2). Furthermore it has been shown that overexpression TIMP-1 is important for growth, 
proliferation and pathogenic differentiation of fibroblasts, which demonstrates an additional role of 
TIMP-1 independent of its inhibition of MMP activity (3, 4). 
Another hallmark of SSc is perivascular infiltration of immune cells, mainly monocytes, which are the 
first immune cells to infiltrate SSc skin (5). Skin infiltrating CD14+ monocytes can secrete profibrotic 
TIMP-1 in SSc patients and TIMP-1 production is enhanced upon TLR8 stimulation by ssRNA (6). 
This raises the possibility that circulating monocytes expressing TIMP-1 migrate into skin and 
contribute to increased deposition of ECM proteins. The important role of monocytes in the 
pathogenesis of fibrotic conditions is further supported by preclinical evidence in mice where 
depletion of monocytes attenuated lung fibrosis after bleomycin challenge, a fibrosis model (7, 8). 
This clearly indicates that monocytes play an important role in the pathogenesis of SSc, however the 
factors and molecular mechanisms promoting TIMP-1 expression are not yet fully defined. 
It has been shown that AP-1 (activator protein 1) family transcription factors, including Fra2 and 
JunD, play a prominent role in pathological ECM production. Studies in an animal model of liver 
fibrosis showed that the AP-1 complex plays a key role in the transcriptional regulation of TIMP-1 
and IL-6 activity. This AP-1 complex contributes to the matrix protein deposition by HSC via their 
trans-differentiation into myofibroblasts-like HSC (9). Removal of specific AP-1 binding sites located 
in the TIMP-1 promoter caused significant reduction of promoter activity in HSCs (10). Another 
study demonstrated that SSc dermal fibroblasts treated with the AP-1 inhibitor T-5224 decreased the 
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expression of collagen and fibronectin in a dose-dependent manner (11). Furthermore, Fra2 transgenic 
mice developed a proliferative vasculopathy of the lung and skin fibrosis, resembling similar disease 
manifestations seen in SSc patients (12). On the other hand, in Fra2 knockout mice, collagen 
expression upon bleomycin administration was strongly reduced, demonstrating that Fra2 is a novel 
downstream mediator for fibrosis development in SSc (13).  
Recently epigenetic modifications including histone acetylation or methylation have been implicated 
in SSc development. Histone demethylation, induced by 3’deazaneplanocin (DZNep), is involved in 
collagen induction (14). It has been shown that DZNep inhibits, whereas Methyl-CpG binding protein 
2 (MeCP2) upregulates expression of histone 3 methyltransferase – Enhancer of zeste homologue-2 
(Ezh2) (15, 16). Ezh2 catalyzes trimethylation of lysine 27 on histone 3 (H3K27me3). Inhibition of 
H3K27me3 by DZNep induced strong expression of Fra2, CTGF and collagen in vivo and in vitro 
models (14). In contrast, inhibition of histone deacetylases (HDACs) by Trichostatin A (TSA) 
decreased collagen expression in bleomycin-treated mice (17, 18). Similarly, murine fibroblasts from 
distal pulmonary arteries treated with apicidin (selective class I HDAC inhibitor) reduced the 
expression of monocyte-attracting chemokine (MCP-1) (19). MCP-1 is a crucial chemokine for the 
recruitment of monocytes and supports a cytokine network maintaining tissue inflammation and 
fibrosis progression, since MCP-1 deficient mice have reduced carbon tetrachloride (CCL4)-induced 
fibrosis (20). Overall, this suggests that histone modifications affect fibrogenesis, which may have 
therapeutic implications. However, a clear understanding of how histone demethylation or acetylation 
can modulate TIMP-1 production in monocytes is still lacking. 
We hypothesised that Fra2 plays a key role in TLR8-mediated TIMP-1 production by SSc monocytes 
and that epigenetic changes affect TIMP-1 production by monocytes. This enhanced production of 
TIMP-1 may initiate myofibroblasts differentiation and consequently fibrosis progression.  
 
Materials and methods 
Patients, controls and bleomycin-induced mouse model 
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Blood donors: thirteen patients with SSc (mean age 61.7 years) and 18 healthy controls (HC) were 
included in the study. All patients with SSc fulfilled the American College of Rheumatology criteria 
according to LeRoy (21). Monocytes from an IRAK4-deficient patient characterised by absent 
cytokine responses to TLR ligands were also used in this study (6). Dermal HC fibroblasts were 
cultured from skin biopsies as described before (22). Skin biopsies from 5 SSc and 5 HC that had 
been formalin fixed and paraffin embedded and sectioned at 10µm were used for qRT-PCR. Briefly 
tissue was deparaffinised using xylene and then rehydrated through descending ethanols (100%-70%) 
and RNA was extracted after proteinase K digestion using the Allprep RNA FFPE kit (Qiagen). 250 
ng of RNA was then reverse transcribed to cDNA. We used bleomycin-induced skin fibrosis in mice, 
to mimic the early-inflammatory stage of SSc. Mice were anesthesised with isoflurane, their backs 
shaved and 100 µl 0.5 mg/ml bleomycin or saline (vehicle) administered via subcutaneous injection to 
an area approximately 1 cm2. Injections were repeated every other day for 4 weeks at which point 
mice were sacrificed.  
Sample collection and cell purification 
Blood was collected in EDTA-coated tubes from HC and SSc patients. Peripheral blood mononuclear 
cells were separated from whole red blood cells as described elsewhere (6).  
Compounds, reagents and in vitro cell cultures  
CD14+ monocytes from HC and SS patients, U937 monocytic cell line or HC fibroblasts were seeded 
in 24-well Costar plates at a concentration of 5×105 cells/ml and cultured for 24 h in 500 µl of RPMI 
(Invitrogen) supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml), L-glutamine (2 mM) 
(all Sigma) and 10% FSC at 37°C in 5% CO2. TLR8 agonist (ssRNA40/LyoVec, InvivoGen), DZNep 
(4703, Tocris), apicidin (A8851, Sigma), TSA (T8552, Sigma), AP-1 inhibitor (SR11302, Tocris), 
recombinant TIMP-1 (PHC8024, Invitrogen), recombinant TGF-β (R&D Systems) and anti-TIMP-1 
antibody (AF970,	  R&D Systems) were kept in sterile conditions in -20oC.  
Microscopic analysis of mouse skin and HC fibroblasts  
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For immunohistochemical analysis, deparaffinised, ethanol dehydrated skin sections from bleomycin 
or saline treated mice were incubated with 20 µg/ml of proteinase K (P2308, Sigma-Aldrich) for 20 
min. at 37°C and stained with rat anti-mouse pan macrophage marker F4/80 (14-4801, eBiocience,) 
and anti-mouse Fra2 (ab1827, Abcam,) primary antibodies overnight at 4°C. Incubation with 
secondary antibodies (goat anti-rabbit-PE, Santa Cruz, sc-3739 and donkey anti-rat-FITC, Jackson 
ImmunoResearch, 712-096-153) was performed for 1 h at RT. For immunocytochemical analysis, HC 
fibroblasts were seeded in 24-well glass coverslips, fixed with 4% PFA and permeabilized with 0.1% 
Triton X-100/PBS for 4  min. Following intense washing, coverslips were incubated with mouse anti-
α-SMA-FITC (A2547, Sigma-Aldrich) for 1 h at RT. Both mouse skin sections and coverslips with 
HC fibroblasts were further analysed by fluorescent microscopy Leica DM4000, using LASAF v4 
software. 
 
Semiquantitative gene expression study 
RNA from freshly isolated monocytes was obtained using TRIzol method. RNA (1000 ng) was 
reverse transcribed to cDNA with the use of random hexamers and the Moloney murine leukaemia 
virus reverse transcriptase enzyme (Invitrogen), according to the manufacturer's protocol. cDNA (20 
ng), forward and reverse primers were used for Fra2 - For-5'-ACGCCGAGTCCTACTCCA-3′, Rev-
5'-TGAGCCAGGCATATCTACCC-3′; TIMP-1 - For-5'-GACGGCCTTCTGCAATTCC-3', Rev-5'-
GTGGTCTGGTTGACTTCTG-3'; Fra1 - For-5'-ACAGATCAGCCCGGAGGAAG-3′, Rev-5'-
CTTCCAGTTTGTCAGTCTCCGC-3′; JunD - For-5'-CAGCGAGGAGCAGGAGTT-3′, Rev-5'-
GAGCTGGTTCTGCTTGTGTAAAT-3′; JunB - For-5'-CACAAGATGAACCACGTGACA-3′, Rev-
5'-GGAGTAGCTGCTGAGGTTGG-3; c-Jun - For-5'-CCAAGGATAGTGCGATGTTT-3′, Rev -5'-
CTGTCCCTCTCCACTGCAAC-3′; Ezh2 - For-5'-TGTGGATACTCCTCCAAGGAA-3′, Rev -
5’GAGGAGCCGTCCTTTTTCA-3′; HDAC3 - For-5'-GGGTGGTGGTGGTTATACTGTC-3′, Rev-
5'-ATGAAACGGGGTCTGAAGTGTGGAGTA-3’; coll 1A1 - For-5′-CAAGAGGAAGGCCAAGT 
CGAGG-3′, Rev-5′-CGTTGTCGCAGACGCAGAT-3; α-SMA - For-5'-CAGGGAGTAATGGTTGG 
AAT-3', Rev-5'-TCTCAAACATAATCTGGGTCA-3'; 18S - For-5′-CGAATGGCTCATTAAA 
TCAGTTATGG-3′, Rev-5′-TATTAGCTCTAGAATTACCACAGTTATCC-3’, MeCP2 – For-5’ 
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GATCAATCCCCAGGGAAAAGC-3’, Rev-5’-CCTCTCCCAGTTACCGTGAAG-3’. Samples 
were analysed in triplicate and normalised to the 18S housekeeping gene using the AB7500 (Applied 
Biosystems) qRT-PCR machine and programme. Expression levels relative to the average healthy 
control (arbitrarily set at 1) were calculated using the following equation: (2^Delta Delta CT)−1 all 
normalised to 18S housekeeping gene.  
Western Blot and ELISA analysis  
Lysates of 5x105 U937 cells were run on 12% SDS PAGE and transferred to membranes and probed 
using rabbit anti-H3K27me3 (SAB4800025, Sigma) or anti-H3 (SAB4500352, Sigma-Aldrich) 
followed by anti-rabbit HRP (DAKO). TIMP-1 protein concentrations in culture supernatants were 
measured by ELISA, according to the manufacturer's protocol (Human TIMP-1 DuoSet, DY970, 
R&D Systems). Signal development was performed using horseradish peroxidase/streptavidin and o-
phenylenediamine dihydrochloride substrate (Sigma-Aldrich) at RT. Fluorescence was measured with 
a plate reader (Tecan, Sunrise). Samples were run in duplicate and serial dilution was performed to 
fall within the detection limits of the assay (0–40 ng/ml). 
Transfection experiment 
HC monocytes were transfected with siFra2 (100 µM), siEzh2 (100 µM) or scramble siRNA (100 
µM) (On-target plus-SMART pool, Dharmacon, UK) using Viromer (Lipocalyx GmbH) for 48 h. 
U937 cells were transfected with DNA fragments of the TIMP-1 promoter cloned downstream of 
luciferase plasmid in a pGL2-basic vector or empty pGL2 at the final concentration of 300 ng using 
1.5 µl of Fugene HD (Promega) transfection reagent per well of a 24 well plate. Renilla plasmid at the 
final concentration of 30 ng was used to normalise transfection efficiency. 24 h after transfection, 
cells were stimulated with TLR8 agonist for an additional 6 hours. Following stimulation, assays for 
reporter gene activity were performed according to Dual-luciferase Promega’s protocol and analysed 
using Glomax multi detection system (Promega, UK). 
Chromatin immunoprecipitation experiments 
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U937 monocytic cell were cultured and stimulated with ssRNA lyovec (Invivogen) at the appropriate 
concentration and after 4 hours cells were fixed in 1% formaldehyde to cross-link chromatin, then 
lysed by sonication, cleared chromatin was then incubated with 4 µg anti Fra2 antibody (sc-604) or 4 
µg control matched isotype antibody, the complexes precipitated, washed and eluted. Crosslinks were 
reversed and cDNA was isolated. qPCR was performed for TIMP-1 promoter region using primers 
proximal For’ ATTTGAGACCCTGGCTTTGG Rev’ GCAGCAGTGGAGGGAGATAA (162bp), 
and distal promoter region For’ CACGCCTGTAATCCCAACAC Rev’ 
CCTCCGGGGTTCAAGAGATT (194bp) the values were normalised to average values of control 
antibody and expressed as fold enrichment above isotype control.  
 
Results 
Marked Fra2 expression in skin-infiltrating macrophages in bleomycin-treated mice and skin 
biopsies from SSc patients 
To confirm that skin-infiltrating macrophages express Fra2 in bleomycin-induced dermal fibrosis, 
immunohistochemical staining of mouse skin sections was performed. It can be seen that 
macrophages (defined by F4/80 antigen expression) accumulating in skin of bleomycin-treated mice 
(Figure 1B) expressed more Fra2 compared to control saline-treated animals (Figure 1A). The white 
arrows indicate the overlay images between F4/80 and Fra2 expression. Fra2 expression was also seen 
in the perivascular area, since vasculopathy is one of the manifestations of SSc progression (23). This 
is consistent with previously published data showing a positive staining of c-Jun, c-Fos (other AP-1 
family members) in fibroblasts, keratinocytes and in endothelial cells of bleomycin-challenged mice 
(11, 24). Specificity of antibodies staining was validated using negative control (Supplemental 
Figure1). Increased expression of Fra2 (p=0.0034) was also seen in skin biopsies from SSc patients 
compared to healthy controls by qPCR (Figure 1C).  
Different expression of AP-1 transcription factors in HC and SSc monocytes  
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It has been shown that Fra2, which is AP-1 family member, plays an important role in organ fibrosis 
therefore we also analysed the expression pattern of all AP-1 members and TIMP-1 in monocytes 
following TLR8 stimulation. HC and SSc monocytes were treated with TLR8 agonist (ssRNA) for 24 
h and gene expression was measured. It can be seen (Figure 2A, B) that both Fra2 (p=0.002, 2.4-fold) 
and TIMP-1 (1.6-fold) increased in TLR8-treated SSc monocytes compared to HC monocytes. In 
contrast, Fra2 and TIMP-1 were repressed in monocytes from an IRAK4-deficient patient upon TLR8 
stimulation, indicating the crucial role of the TLR signaling pathway in Fra2 and TIMP-1 induction. 
This patient has a genetic lesion in IRAK-4 that leads to no IRAK-4 protein production. Interestingly, 
there was also a positive correlation between Fra2 and TIMP-1 expression in SSc monocytes (p=0.02) 
upon TLR8 stimulation (Supplemental Figure 2), but not in HC (p=0.38), which corroborates Fra2-
mediated TIMP-1 expression in diseased monocytes. Surprisingly, the basal level of TLR8 was 2.1-
fold lower (p=0.037) in SSc monocytes compared to HC monocytes (Figure 2C). The same tendency 
was observed following ssRNA stimulation showing 1.6-fold lower expression of TLR8 in SSc 
monocytes compared to HC. This suggests that diseased monocytes may have an altered downstream 
signaling pathway maintaining strong Fra2 and TIMP-1 expression despite reduced expression of 
TLR8.  
We also analysed the expression of other AP-1 members in HC and SSc monocytes. As expected, 
Fra1 was significantly downregulated in TLR8-treated (p=0.03) and untreated (p=0.01) SSc 
monocytes compared to HC (Figure 2D). The expression of other AP-1 family members including 
JunD (Figure 2G) and JunB (Figure 2E) did not differ significantly between HC and SSc monocytes 
apart from the basal level of c-Jun, which was significantly downregulated (p=0.04) in SSc monocytes 
(Figure 2F). This indicates that only Fra2 plays a pivotal role during TLR8 stimulation in SSc 
monocytes.  
TLR8 agonist induces TIMP-1 expression via AP-1 family member - Fra2  
To test that TIMP-1 production is Fra2 dependent, HC and SSc monocytes were pre-treated with an 
AP-1 inhibitor prior to TLR8 stimulation. It can be seen (Figure 3A) that pre-treatment for 2 h with an 
AP-1 chemical inhibitor (SR 11302) significantly reduced TIMP-1 production in HC (p=0.03) and 
10	  
	  
SSc (p=0.02) monocytes stimulated with the TLR8 ligand. We used a different dilutions of AP-1 
inhibitor (data not shown) and the concentration of 20 µM of AP-1 inhibitor was the most optimal for 
TIMP-1 inhibition and also did not affect cell viability, as determined by MTS assay (Figure 3B). In 
order to exclude off-target effects from AP-1 chemical inhibitor we performed Fra2 silencing in TLR8 
stimulated primary HC monocytes. It can be seen in Figure 3C that genetic inactivation of Fra2 
significantly (p=0.0068) reduced TIMP-1 expression. In contrast, TLR8 stimulated monocytes 
transfected with scramble siRNA did not display reduced TIMP-1 expression. To confirm Fra2 
knockdown, Fra2 expression also was measured in primary monocytes (Supplemental Figure 3). We 
next measured the TIMP-1 promoter activity in the presence of TLR8 agonist in the human monocytic 
U397 cell line, since primary monocytes are difficult to transfect. U397 cells were transfected with a 
plasmid where TIMP-1 promoter was cloned downstream of firefly luciferase gene. We used renilla 
plasmid to normalise TIMP-1 plasmid expression in untreated, TLR8-treated or empty pGL-2 vector 
transfected cells. As seen in Figure 3D, TIMP-1 promoter activity was significantly increased in 
TLR8-treated cells compared to untreated (p=0.01) and cells transfected with empty vector (p=0.001), 
respectively. This suggests that both gene expression and promoter activity of TIMP-1 are increased 
upon TLR8 stimulation in monocytes. In order to determine whether TIMP-1 could be 
transcriptionally regulated by Fra-2, we performed ChIP analysis in TLR8 stimulated U937 cells 
(Figure 3E). We found that Fra2 was able to bind the TIMP-1 promotor in the proximal rather than a 
distal region (7-fold enrichment, p	  < 0.0001) suggesting a direct transcriptional activation of TIMP-1 
by Fra-2.  
TLR8 -mediated TIMP-1 production and its regulation by histone modification in U937 cells 
Since epigenetic modifications are important in regulating fibrosis, we investigated the role of histone 
modification on Fra2 and TIMP-1 expression upon 24 h DZNep or TSA-treatment in U937 cells, a 
monocytoid cell line. It can be seen that DZNep (reducing H3K27me3) treatment significantly 
increased Fra2 expression (Figure 4A, p=0.01), while TIMP-1 expression was only moderately 
elevated (Figure 4B). In contrast, TSA (inducing histone acetylation) treatment significantly reduced 
the expression of Fra2 (p<0.001) and TIMP-1 (p=0.01). Western blot analysis confirmed the specific 
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activity of DZNep, because the level of H3K27me3 was reduced in DZNep-treated compared to 
untreated cells (Figure 4C). The total histone 3 (H3) was used as a loading control across groups. The 
MTS test showed no significant changes in U937 cell viability upon TSA or DZNep treatment (Figure 
4D).  
Synergistic effect of TLR8 agonist and DZNep on Fra2 and TIMP-1 expression in HC 
monocytes 
As seen before (Figure 4A), DZNep alone induces only a 2-fold upregulation of Fra2 in U937 cells, 
therefore we asked if combination of TLR8 agonist and DZNep can synergistically enhance Fra2 and 
TIMP-1 expression in primary HC monocytes. To test this hypothesis, HC monocytes were pre-
treated with DZNep for 4 h and then stimulated with TLR8 agonist. The level of Fra2 and TIMP-1 
was significantly increased in DZNep+TLR8-treated monocytes compared to monocytes stimulated 
with TLR8 or DZNep alone (Figure 5A, B). Furthermore, combined DZNep+TLR8 activation altered 
monocytes morphology, displayed as cell aggregations and elongated shape formation (Supplemental 
Figure 4). This suggests that DZNep+TLR8 synergistically induce strong Fra2 and TIMP-1 
expression, which mirrors the changes seen in cell morphology. In contrast, pre-treatment with 
apicidin, which is more specific HDAC inhibitor than TSA, repressed the expression of Fra2 and 
TIMP-1 upon TLR8 stimulation. Also the morphology of apicidin+TLR8-treated monocytes remained 
as untreated (Supplemental Figure 4). The results from ELISA showed a similar pattern of 
DZNep+TLR8-mediated upregulation and apicidin+TLR8-mediated reduction of secreted TIMP-1 
(Figure 5C). The MTS test showed no changes in cell viability in DZNep or apicidin-treated HC 
monocytes indicating that these concentrations are not toxic (Figure 5D).  
We then investigated if the expression level of Ezh2, the enzyme involved in H3K27me3 modification 
and part of the polycomb repressive complex 2, is altered in HC and SSc monocytes upon TLR8 
stimulation. DZNep is also involved in Ezh2 inhibition. The constitutive basal level of Ezh2 was 
significantly higher in SSc monocytes compared to HC monocytes (p=0.01) and was even more 
increased upon TLR8 stimulation in both HC and SSc monocytes (Figure 5E). We also measured the 
expression level of HDAC3, which can be specifically inhibited by apicidin. Although the basal level 
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of HDAC3 was higher in SSc monocytes than in HC (p=0.01), TLR8 stimulation did not change the 
HDAC3 expression in SSc monocytes. Only in TLR8-stimulated HC monocytes, HDAC3 expression 
was significantly increased compared to untreated (Figure 5F).  
TLR8 agonist and DZNep treatment of HC monocytes induces fibroblasts trans-differentiation 
via TIMP-1 
Finally, to evaluate the functional effect of monocytes-derived TIMP-1 on HC fibroblasts trans-
differentiation, HC monocytes were stimulated with TLR8 agonist and different histone modifiers. To 
test this, HC monocytes were pre-treated for 4 h with DZNep or apicidin or transfected with siEzh2 
for 24 h and vigorously washed in order to remove residual histone modifiers, since they could have a 
direct effect on collagen production in fibroblasts. Next, HC monocytes were additionally treated with 
TLR8 agonist to induce enhanced TIMP-1 production and inserted into trans-wells physically 
separating monocytes population from adherent HC fibroblasts. 48 h later, profibrotic markers 
including α-SMA (Figure 6A) and collagen (Figure 6B) were determined in HC fibroblasts co-
cultured with TIMP-1-producting monocytes. DZNep+TLR8 or siEzh2+TLR8 treatment of HC 
monocytes induced significant upregulation of collagen and α-SMA genes in HC fibroblasts 
compared to untreated or apicidin+TLR8-treated HC monocytes. In addition using 
immunocytochemistry, HC fibroblasts showed a positive staining for α-SMA in the presence of 
monocytes stimulated with DZNep+TLR8 (Figure 6C). To confirm that α-SMA expression is induced 
by TIMP-1-producing monocytes, HC fibroblasts were also directly stimulated with human 
recombinant TIMP-1. Figures 6D and 6E have shown that HC fibroblasts stimulated with TIMP-1 
significantly upregulated the expression α-SMA but not collagen. However, pre-treatment HC 
fibroblasts with a TIMP-1 neutralising antibody 2 h prior TIMP-1 treatment significantly reduced the 
expression level of α-SMA compared to fibroblasts treated only with TIMP-1 (Figure 6F). Isotype 
control antibody did not have any effect on the α-SMA production. As a positive control for α-SMA 
induction, HC fibroblasts were stimulated with TGF-β a known inducer.  
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Discussion 
Previous results from our group have shown that monocytes from SSc patients contribute to the 
imbalance between TIMP-1 and MMPs upon TLR8 agonist stimulation (ssRNA) (6), but the role of 
the Fra2 transcription factor in TIMP-1 regulation is unknown. Fra2 is involved in several biological 
processes including differentiation, proliferation and oncogene transformation, but also is a 
downstream mediator promoting fibrogenesis (13, 24). 
In this study we demonstrate that TLR8-mediated overexpression of TIMP-1 in SSc monocytes is 
mediated via Fra2. In addition, histone demethylation due to DZNep treatment enhances Fra2 and 
TIMP-1 expression in monocytes in the presence of TLR8 agonist and consequently induces 
fibroblasts trans-differentiation to myofibroblasts; the cell type responsible for excess ECM. In 
particular, we showed that Fra2 was upregulated in skin infiltrating macrophages in bleomycin-
induced skin fibrosis, mimicking the early-inflammatory stage of SSc progression (25) and in skin 
biopsies from SSc patients. Furthermore, we showed a positive correlation between Fra2 and TIMP-1 
expression induced by TLR8 stimulation in SSc monocytes, but not in HC monocytes, whereas TLR8 
stimulation of an IRAK-4-deficient patient did not induce neither Fra2 nor TIMP-1 expression. Also, 
activation of Fra2 via TLR8 agonist was crucial for TIMP-1 induction, since an AP-1 inhibitor 
prevented TIMP-1 secretion in SSc monocytes. Similarly ChIP analysis confirmed direct in vivo 
activation of the TIMP-1 promoter by Fra2 in TLR8 stimulated U937 cells. Taken together these 
results confirm that Fra2 acts as a positive regulator of TIMP-1 production upon TLR8 stimulation by 
transactivating TIMP-1. In contrast, Fra1 expression was significantly reduced in SSc monocytes. The 
effect of Fra1 has been previously reported in Fra1 knockout mice, where Fra1 depletion resulted in 
exaggerated pulmonary fibrosis due to increased TIMP-1, collagen and TGF-β expression (26), while 
overexpression of Fra-1 in mice reduced proinflammatory cytokine production (27). On the other 
hand some studies have shown that Fra1 transgenic mice spontaneously developed biliary fibrosis 
(28). Further studies are needed to confirm whether Fra1 is a faithful biomarker in SSc.  
To further investigate the role of TLR8 in TIMP-1 induction, U937 monocytic cells were transfected 
with a plasmid encoding the TIMP-1 promoter, which was cloned downstream of firefly luciferase 
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gene. The luciferase activity was significantly increased in the presence of TLR8 agonists, but not in 
untreated cells, confirming TIMP-1 activity is governed by TLR8 signaling.  
Furthermore, DZNep-treated U937 cells increased the expression of Fra2 and TIMP-1, in contrast to 
TSA-treated cells. Western blot analysis corroborates the specificity of DZNep treatment, as the 
activity of H3K27me3 was reduced in DZNep-stimulated U937 cells. Histones in the chromatin 
undergo multiple post translational modifications that regulate gene expression and include 
acetylation and deacetylation by HDACs. A similar result of DZNep-dependent Fra2 induction has 
been previously shown in dermal HC fibroblasts (14). Interestingly, administration of DZNep to 
bleomycin-treated mice (inducing skin fibrosis) even further increased the number of fibroblasts 
expressing Fra2, a transcription factor regulating TIMP-1 (14). In contrast, administration of DZNep 
to mice during acute CCL4-induced injury (inducing liver fibrosis) decreased the expression of 
collagen and TIMP-1 (15). This suggests that DZNep may have the opposite effect on profibrotic 
genes expression due to organ specificity.  
To further elucidate the role of histone modification(s) and TLR8 agonist on Fra2 and TIMP-1 
expression, HC monocytes were stimulated with DZNep or apicidin alone or in combination with 
TLR8 agonist. Enhanced expression of Fra2 and TIMP-1 was observed when HC monocytes were 
stimulated with both DZNep and TLR8, than DZNep or TLR8 alone. This suggests that initial 
epigenetic changes included by DZNep dynamically modifies chromatin architecture allowing the 
TLR8 agonist to be a powerful stimulator of Fra2 transcription factor, which consequently enhances 
TIMP-1 production. In contrast chromatin alterations induced by apicidin may prevent TLR8 
stimulation to activate Fra2, thereby repressing TIMP-1. Interestingly, blockade of HDACs through 
HDAC class I inhibitors supresses angiotension II-mediated cardiac fibrosis, a model of heart fibrosis 
in the mouse. This was demonstrated by inhibiting ‘activation’ of cardiac fibroblasts and also by 
differentiation of fibrocytes from bone marrow cells (29). This is important as fibrocytes can develop 
from bone marrow-originated monocytes (30). 
Surprisingly, the level of Ezh2 was 4.8-fold higher in SSc monocytes than HC basally and TLR8 
stimulation even further enhanced Ezh2 expression. Ezh2 is part of the polycomb repressive complex 
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important in mediating chromatin modifications. Ezh2 is overexpressed in many cancers (31, 32). 
Similar data were previously published by Kramer et at, showing the upregulation of H3K27me3 due 
to Ezh2 activity in fibroblasts from SSc patients compared to HC fibroblasts. These results were 
explained by potential compensatory mechanism that regulates the profibrotic genes in SSc patients 
(14). In addition, MeCP2 has been shown to upregulates Ezh2 expression (24). We found high 
expression of MeCP2 in SSc skin biopsies compared to HC (data not shown). Therefore, the higher 
expression of Ezh2 in our system may be due to the elevated MeCP2 levels in SSc patients. 
Interestingly MeCP2 has been identified as a SNP conferring risk in SSc in a genome wide 
association study [27]. 
Although the expression of HDAC3, an example of class I HDACs repressed by apicidin, was 
significantly upregulated in HC monocytes upon TLR8 stimulation, it was not changed in TLR8-
treated SSc monocytes. This suggests that HDAC3-dependent deacetylation does not play a 
significant role in SSc pathogenesis, or at least during TLR8 stimulation. Finally, we assessed the 
functional effect of DZNep+TLR8-treated monocytes on fibroblasts differentiation. Co-culture of 
DZNep+TLR8-treated or siEzh2+TLR8-treated monocytes with HC fibroblasts significantly 
upregulated the expression of α-SMA and collagen genes in fibroblasts. Furthermore, HC fibroblasts 
exhibited a positive staining for α-SMA, which is considered to be the marker for myofibroblasts (the 
effector cells in fibrosis). This confirms that DZNep+TLR8, but not apicidin+TLR8-treated 
monocytes induce production of TIMP-1, which has the ability to trans-differentiate fibroblasts 
toward pathogenic myofibroblasts. We have also demonstrated that HC fibroblasts directly stimulated 
with recombinant TIMP-1 upregulate α-SMA but not collagen expression. Neutralising anti-TIMP-1 
antibody inhibited α-SMA expression, confirming an additional role of TIMP-1 as a growth factor 
regulating fibroblasts differentiation. This further shows the link between inflammatory cells and 
fibrosis in SSc and underpins a complex sequence of events beginning with innate immune activation. 
Our observations are consistent with previous findings showing that adenovirus-mediated 
overexpression of TIMP-1 significantly increased α-SMA in cardiac fibroblasts but had no effect on 
collagen production (3). Although in this study we demonstrated DZNep+TLR8-dependent TIMP-1 
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production, we cannot exclude the possibility that other factors promoting fibroblasts differentiation 
may also be induced following DZNep+TLR8 stimulation including TGF-β. This needs to be tested in 
the further experiments.  
Overall, these results showed that selective, epigenetic modification of monocytes can either promote 
or repress myofibrogenic differentiation, and hence impact on the pathogenesis of SSc. A growing 
appreciation of the role of epigenetics in SSc and fibrosis is garnered and currently there are 
epigenetic drugs in use clinically for other indications (33).  
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Supplemental Figure 1. Negative control (no primary) of Fra2 and F4/80 staining of mice skin section.
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Supplemental Figure 2. HC (n=13) and SSc monocytes (n=14) were stimulated with 2 µg/ml TLR8 agonist (ssRNA) for 
24 h and correlation between TIMP-1 and Fra2 gene expression in HC and SSc monocytes was measured. 
Supplemental Figure 3. HC monocytes (n=4) were transfected with Fra2 siRNA or scramble siRNA and 48 h 
later Fra2  expression was measured. 
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Supplemental Figure 4. The effect of TLR8 stimulation and histone modifications on morphological changes in HC monocytes.
HC monocytes were treated with TLR8 alone or in combination with DZNep or Apicidin for 24 h and morphological changes 
were observed using light microscope. Black arrows indicate cells aggregation and white arrow indicates elongated shape. 
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